TD Cowen lowered the firm’s price target on Novavax (NVAX) to $9 from $14 and keeps a Hold rating on the shares. The firm said the FDA lifted its clinical hold on its COVID/flu combo and standalone ...
Novavax (NVAX) delivered earnings and revenue surprises of 12.64% and 47.43%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
On Friday, Novavax Inc (NVAX) stock saw a decline, ending the day at $8.91 which represents a decrease of $-0.27 or -2.94% from the prior close of $9.18. The stock opened at $9.25 and touched a low of ...